Kvalitena AB (publ) publicerar kvartalsrapport för Q1 2023
Kvalitena publicerar kvartalsrapport för Q1 2023
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m
Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release
Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo
Wereldhave announces reappointment of Supervisory Board member Hein Brand at Annual General Meeting of Shareholders24.4.2024 15:31:42 CEST | Press release
Wereldhave is pleased to announce the reappointment of Mr. Hein Brand as member of the Supervisory Board, as approved by the Annual General Meeting of shareholders (AGM) of Wereldhave N.V. In his role as Vice President of the Supervisory Board and Chairman of the Audit Committee, Mr Brand will continue to provide valuable leadership and guidance to the company for a period of two years, ending at the Annual General Meeting in April 2026. Full voting results of the Annual General Meeting will be published on the Company website. Attachment PB CORP 24-04-2024 - Wereldhave AGM reappoints Mr Hein Brand as Supervisory Board member
Leadership Evolution: Zafin Announces Strategic CEO Transition to Propel Future Growth24.4.2024 15:15:00 CEST | Press release
Al Karim Somji to Transition Leadership to Charbel Safadi as Part of Zafin's Long-Term Success Strategy VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Zafin, the leading provider of SaaS core modernization and transformation solutions for banks, today announced a strategic leadership transition that has been part of the company’s long-term success plan. After more than two decades of exemplary leadership, Al Karim Somji will step down as Chief Executive Officer of Zafin. He will continue to serve as an ongoing member of the Board of Directors. As a founder of the Company, Al Karim has been pivotal in shaping Zafin's success, leaving a lasting legacy of excellence and innovation. Under his stewardship, Zafin has experienced significant growth and success, reinforcing its status as a leader in global banking technology. As an active board member and substantial owner, Al Karim will provide essential insight and guidance to ensure a smooth leadership transition. His exten
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership24.4.2024 15:00:00 CEST | Press release
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo. Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cy